Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci178617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Yuru Shen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Diseases and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Paclitaxel, Myeloid-Derived Suppressor Cells, Ginsenosides, Macaca fascicularis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Liposomal drug delivery systems have revolutionized traditional cytotoxic drugs. However, the relative instability and toxicity of the existing liposomal drug delivery systems compromised their efficacy. Herein, we present Rg3-lipo, an innovative drug delivery system using a glycosyl moiety–enriched ginsenoside (Rg3). This system is distinguished by its glycosyl moieties exposed on the liposomal surface. These moieties imitate human cell membranes to stabilize and evade phagocytic clearance. The Rg3-lipo system loaded with paclitaxel (PTX-Rg3-lipo) demonstrated favorable bioavailability and safety in Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys. With its glycosyl moieties recognizing tumor cells via the glucose transporter Glut1, PTX-Rg3-lipo inhibited gastric, breast, and esophageal cancers in human cancer cell lines, tumor-bearing mice, and patient-derived xenograft models. These glycosyl moieties selectively targeted myeloid-derived suppressor cells (MDSCs) through the glucose transporter Glut3 to attenuate their immunosuppressive effect. The mechanism study revealed that Rg3-lipo suppressed glycolysis and downregulated the transcription factors c-Maf and Mafb overcoming the MDSC-mediated immunosuppressive microenvironment and enhancing PTX-Rg3-lipo’s antitumor effect. Taken together, we supply substantial evidence for its advantageous bioavailability and safety in multiple animal models, including nonhuman primates, and Rg3-lipo’s dual targeting of cancer cells and MDSCs. Further investigation regarding Rg3-lipo’s druggability will be conducted in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Digestive Diseases and National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
- Biotherapy Research Center, Fudan University, Shanghai, China.
- Xiamen Ginposome Pharmaceutical Co. Ltd., Xiamen, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shen, Y., Zhong, B., Zheng, W., Wang, D., Chen, L., Song, H., Pan, X., Mo, S., Jin, B., Cui, H., Zhan, H., Luo, F., & Liu, J. (2024). Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci178617
Vancouver
Shen Y, Zhong B, Zheng W, Wang D, Chen L, Song H, et al. Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells. Journal of Clinical Investigation. 2024. doi:10.1172/jci178617
BibTeX
@article{Shen2024,
author = {Shen, Yuru and Zhong, Bin and Zheng, Wanwei and Wang, Dan and Chen, Lin and Song, Huan and Pan, Xuanxuan and Mo, Shaocong and Jin, Bryan and Cui, Haoshu and Zhan, Huaxing and Luo, Feifei and Liu, Jie},
title = {Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci178617}
}
EUVIMED